Benjamin Weide

11.8k total citations · 1 hit paper
74 papers, 3.6k citations indexed

About

Benjamin Weide is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Benjamin Weide has authored 74 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 33 papers in Molecular Biology and 32 papers in Immunology. Recurrent topics in Benjamin Weide's work include Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Cutaneous Melanoma Detection and Management (19 papers). Benjamin Weide is often cited by papers focused on Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Cutaneous Melanoma Detection and Management (19 papers). Benjamin Weide collaborates with scholars based in Germany, United States and Switzerland. Benjamin Weide's co-authors include Claus Garbe, Thomas Eigentler, Graham Pawelec, Steve Pascolo, Annette Pflugfelder, Birgit Scheel, Ingmar Hoerr, Hans‐Georg Rammensee, Evelyna Derhovanessian and Henning Zelba and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Benjamin Weide

73 papers receiving 3.6k citations

Hit Papers

Ipilimumab-dependent cell-mediated cytotoxicity of regula... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
    2015 460 citations Monika Kusio-Kobiałka, Periklis Foukas et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Weide Germany 29 2.1k 2.0k 1.4k 323 285 74 3.6k
Ryan Emerson United States 32 2.2k 1.0× 2.6k 1.3× 1.0k 0.7× 281 0.9× 291 1.0× 64 4.5k
Joshua Brody United States 35 2.8k 1.3× 3.0k 1.5× 1.1k 0.8× 273 0.8× 130 0.5× 147 4.9k
Laura Bover United States 26 926 0.4× 2.3k 1.2× 936 0.7× 329 1.0× 273 1.0× 58 3.7k
Robert M. Conry United States 31 1.9k 0.9× 1.2k 0.6× 1.6k 1.1× 542 1.7× 208 0.7× 87 3.3k
Maria Pia Protti Italy 29 1.3k 0.6× 2.4k 1.2× 1.4k 1.0× 158 0.5× 245 0.9× 80 3.9k
Erik Hooijberg Netherlands 34 1.4k 0.6× 2.0k 1.0× 1.1k 0.8× 348 1.1× 291 1.0× 95 3.2k
Vijay Bhoj United States 17 2.0k 0.9× 1.3k 0.7× 916 0.6× 586 1.8× 278 1.0× 39 3.4k
Kevin Gorski United States 21 2.4k 1.1× 2.9k 1.4× 1.0k 0.7× 1.0k 3.2× 402 1.4× 29 4.9k
Pier Paolo Piccaluga Italy 40 2.1k 1.0× 1.4k 0.7× 1.3k 0.9× 186 0.6× 329 1.2× 208 5.8k
John G. Frelinger United States 32 1.8k 0.9× 2.5k 1.2× 1.2k 0.8× 362 1.1× 191 0.7× 88 4.3k

Countries citing papers authored by Benjamin Weide

Since Specialization
Citations

This map shows the geographic impact of Benjamin Weide's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Weide with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Weide more than expected).

Fields of papers citing papers by Benjamin Weide

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Weide. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Weide. The network helps show where Benjamin Weide may publish in the future.

Co-authorship network of co-authors of Benjamin Weide

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Weide. A scholar is included among the top collaborators of Benjamin Weide based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Weide. Benjamin Weide is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hofmann, Maja A., Ulrike Keim, Andrea Forschner, et al.. (2020). Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknesses. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 18(7). 682–690. 7 indexed citations
2.
Weide, Benjamin, Thomas Eigentler, Chiara Catania, et al.. (2019). A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology Immunotherapy. 68(9). 1547–1559. 41 indexed citations
3.
Schilling, Bastian, Alexander Martens, Marnix H. Geukes Foppen, et al.. (2019). First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology Immunotherapy. 68(5). 765–772. 27 indexed citations
4.
Gassenmaier, Maximilian, Thomas Eigentler, Ulrike Keim, et al.. (2017). Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. Journal of Investigative Dermatology. 137(12). 2570–2577. 17 indexed citations
5.
Weide, Benjamin, Dario Neri, & Giuliano Elia. (2017). Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunology Immunotherapy. 66(5). 647–656. 30 indexed citations
6.
Hassel, Jessica C., Kristina Buder‐Bakhaya, Carolin Bender, et al.. (2017). Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Medicine. 7(1). 95–104. 13 indexed citations
7.
Weide, Benjamin, Tina Schäfer, Alexander Martens, et al.. (2016). High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma. Journal of Investigative Dermatology. 136(12). 2444–2452. 29 indexed citations
8.
Jacquelot, Nicolas, David Enot, Sylvie Rusakiewicz, et al.. (2016). Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology. 136(5). 994–1001. 22 indexed citations
9.
Martens, Alexander, Kilian Wistuba‐Hamprecht, Jianda Yuan, et al.. (2016). Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research. 22(19). 4848–4858. 141 indexed citations
10.
Wistuba‐Hamprecht, Kilian, Alexander Martens, Benjamin Weide, et al.. (2016). Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. The Journal of Immunology. 198(2). 927–936. 27 indexed citations
11.
Satzger, Imke, Peter Mohr, Lisa Zimmer, et al.. (2015). Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation?. Melanoma Research. 25(4). 362–366. 19 indexed citations
12.
Zelba, Henning, Benjamin Weide, Alexander Martens, et al.. (2014). Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research. 20(16). 4390–4399. 35 indexed citations
13.
Weide, Benjamin, Thomas Eigentler, Annette Pflugfelder, et al.. (2014). Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses. Cancer Immunology Research. 2(7). 668–678. 77 indexed citations
14.
Zelba, Henning, Benjamin Weide, Alexander Martens, et al.. (2014). The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma. OncoImmunology. 4(1). e955683–e955683. 4 indexed citations
15.
Romano, Emanuela, Monika Kusio-Kobiałka, Periklis Foukas, et al.. (2014). FcgRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients. Journal for ImmunoTherapy of Cancer. 2(S3). 4 indexed citations
16.
Weide, Benjamin, Alexander Martens, Henning Zelba, et al.. (2013). Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells. Clinical Cancer Research. 20(6). 1601–1609. 210 indexed citations
17.
Weide, Benjamin, Petra Büttner, Ulrike Leiter, et al.. (2013). Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy. PLoS ONE. 8(11). e81624–e81624. 52 indexed citations
18.
Weide, Benjamin, Henning Zelba, Evelyna Derhovanessian, et al.. (2012). Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. Journal of Clinical Oncology. 30(15). 1835–1841. 90 indexed citations
19.
Eigentler, Thomas, Benjamin Weide, Filippo de Braud, et al.. (2011). A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. Clinical Cancer Research. 17(24). 7732–7742. 125 indexed citations
20.
Eigentler, Thomas, Benjamin Weide, Helmut Breuninger, et al.. (2007). A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology. 57(4). 616–621. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryan Emerson Breakdown of academic impact, for papers by Joshua Brody Breakdown of academic impact, for papers by Laura Bover Breakdown of academic impact, for papers by Robert M. Conry Breakdown of academic impact, for papers by Maria Pia Protti Breakdown of academic impact, for papers by Erik Hooijberg Breakdown of academic impact, for papers by Vijay Bhoj Breakdown of academic impact, for papers by Kevin Gorski Breakdown of academic impact, for papers by Pier Paolo Piccaluga Breakdown of academic impact, for papers by John G. Frelinger
Rankless by CCL
2026